FDA and AACR to Host Workshop on Multiple Myeloma Disparities and African American Representation in Clinical Trials
The U.S. Food and Drug Administration (FDA) and the American Association for Cancer Research (AACR) will host the upcoming FDA-AACR Workshop to Examine Under-representation of African Americans in Multiple Myeloma Clinical Trials.
African Americans are disproportionately affected by multiple myeloma, having a two- to three-fold higher incidence compared with whites and representing 20 percent of the multiple myeloma patients in the United States. Despite this difference in incidence, African Americans have historically been underrepresented in clinical trials for multiple myeloma therapies.
This workshop will bring together researchers, physicians, patients, industry representatives, and regulators to discuss the biology, genetics, and clinical factors underlying disparities in multiple myeloma; the implications of limited clinical data for racial and ethnic minorities with multiple myeloma; and recommendations for improving representation in clinical trials and otherwise increasing our knowledge of how and whether anti-myeloma therapies work in racial and ethnic minorities.
This post on the AACR’s blog summarizes the issue and provides more details about the workshop, including insight from the cochairs.
Thursday, February 13
8 a.m.-5 p.m. ET
Washington Marriott at Wardman Park
2660 Woodley Road NW
Washington, DC 20008
Live streaming is available for reporters interested in covering remotely. Please register with Julia Gunther at [email protected] to receive the link.
Workshop cochair Kenneth C. Anderson, MD, FAACR, is available for media interviews. Anderson serves as chair of the AACR Regulatory Science and Policy Subcommittee, and is program director of the Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics and chief of the Division of Hematologic Neoplasia at Dana-Farber Cancer Institute.
View the agenda with all speakers here.
To RSVP attendance or schedule an interview, please contact Julia Gunther at [email protected] or 215-446-6896.